Oral anticoagulation is obligatory in patients with atrial fibrillation (AF) to prevent
thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety …

Highlights•Direct oral anticoagulants did not increase stroke or systemic embolism event
rate.•Direct oral anticoagulants had lower major bleeding rate than warfarin.•Direct oral …

Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …

Background Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …

Background: Real-world data show limited utilization of direct oral anticoagulants (DO-ACs)
in obese patients (body mass index [BMI]≥ 30 kg/m2) due to concerns regarding their …

Abstract Background and Aim Obesity affects nearly 650 million adults worldwide, and the
prevalence is steadily rising. This condition has significant adverse effects on cardiovascular …

Background: Limited real-world data exist on the comparative effectiveness and safety of
direct oral anticoagulants (DOACs) compared to warfarin in obese patients with atrial …

Objectives Obesity is associated with increased risks of atrial fibrillation (AF) and venous
thromboembolism (VTE) for which anticoagulation is commonly used. However, data on the …

Background: The International Society of Thrombosis and Haemostasis recommends
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …

In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …